Global Hunter Reiterates Buy on Auxilium Pharmaceuticals (AUXL)

Global Hunter is out with its report today on Auxilium Pharmaceuticals (NASDAQ: AUXL), reiterating Buy.

In a note to clients, Global Hunter writes, "Upcoming events for Auxilium include Q1 earnings and a three-year safety update in patients with Dupuytren's contracture expected in June. In addition, we anticipate clarity regarding the regulatory pathway in Japan this year and additions of other ROW partnerships. In our view, there remains significant upside to our fair value giving our long-term growth prospects and attractive valuation. We continue to anticipate shares to appreciate during the XIAFLEX launch with the potential realization of catalysts providing upside to our estimates. Thus, we reiterate our Buy rating and $27 price target."

At the time of posting, shares of AUXL were trading at $21.99, down 0.09% from Tuesday's close.